phase clinical plasma cellular pharmacology study gemcitabine novel deoxycytidine analog gemcitabine dFdC phase clinical pharmacology trial minutes weekly times weeks weeks maximum-tolerated dose MTD dose-limiting toxicity myelosuppression thrombocytopenia anemia important granulocytopenia Nonhematologic toxicity minimal responses patients adenocarcinomas colon lung maximum dFdC plasma concentration minutes infusion proportional total dose Elimination due deamination rapid terminal half-life minutes dose independent deamination product dFdU biphasic kinetics long terminal phase hours sole metabolite urine concentration dFdC mononuclear cells proportion dFdC dose infusions increment dFdC dFdCTP doses plasma dFdC concentrations mumol/L saturation dFdC accumulation recommended dose phase II clinical trials solid tumors 